Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,149.41 +2.66 (+0.23%)
Streaming Delayed Price Updated: 2:25 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
34 35 Next >
Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?
Checkmate Pharmaceuticals (CMPI) stock is rocketing higher on Tuesday following news that Regeneron Pharmaceuticals (REGN) is acquiring it. 
Via InvestorPlace
38 Stocks Moving In Tuesday's Mid-Day Session
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) climbed 329.2% to $10.43 after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to acquire the company for $... 
Via Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Analyst Ratings for Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Regeneron Builds On Retinal Disease Expertise Via Gene Therapy Pact With ViGeneron
Via Benzinga
Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal
Via Benzinga
Why Checkmate Pharmaceuticals Shares Are Skyrocketing
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to... 
Via Benzinga
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting... 
Via Benzinga
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago. 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy
Via Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
Healthcare Stocks Lead the Way Up as the Market Fades
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions. 
Via Talk Markets
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Michael Grimm Purchases $5.66 Million Worth Of Energy Transfer & Other Notable Insider Buys
Natural gas prices were range bound for the better part of the last decade, oscillating between $2 and $4 per million British thermal units (MMBtu) with the occasional spike... 
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
Raytheon, Shell Lead Five Stocks Setting Up, Breaking Out From Strong Sectors
Raytheon and Shell are just below buy points. They have good company. 
Via Investor's Business Daily
Is It Time To Tweak Your Investments For An Inflationary Environment?
Is it time to tweak your investing portfolio to adapt to the potential for long-term inflation? Here are ways to do so. 
Via Investor's Business Daily
This Is What Whales Are Betting On Regeneron Pharmaceuticals
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 11 strange... 
Via Benzinga
Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating
On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier. 
Via Investor's Business Daily
Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92
On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92. 
Via Investor's Business Daily
Stocks That Hit 52-Week Highs On Thursday
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals Inc?
Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) short percent of float has risen 4.85% since its last report. The company recently reported that it has 2.24 million shares sold... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Europe Approves Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6-11 Years With Type 2 Inflammation
The  
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 11.29% on an annualized basis producing an average annual return of 18.54%. Currently, Regeneron... 
Via Benzinga
Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90
On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago. 
Via Investor's Business Daily
7 Safe Stocks to Buy to Guard Against a Recession
It's not too late to buy safe stocks. These seven stocks, all A-rated, are perfect plays for riding out continued volatility in the markets. 
Via InvestorPlace
Annual Boosters Might Not Give Moderna the Boost It Needs
With the vaccine maker's shares appearing fully priced based on next year's earnings, don't count on a full MRNA stock recovery. 
Via InvestorPlace
Good Entry Point for Biotech Stocks
Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms. 
Via Talk Markets
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.